109 related articles for article (PubMed ID: 31971110)
1. Ursodeoxycholic Acid (UDCA) Promotes Lactate Metabolism in Mouse Hepatocytes through Cholic Acid (CA) - Farnesoid X Receptor (FXR) Pathway.
Wang L; He HW; Zhou X; Long Y
Curr Mol Med; 2020; 20(8):661-666. PubMed ID: 31971110
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic Acid (UDCA) Reduces Hepatocyte Apoptosis by Inhibiting Farnesoid X Receptor (FXR) in Hemorrhagic Shock (HS).
Wang L; Rui X; He HW; Zhou X; Long Y
Curr Mol Med; 2023; 23(6):550-558. PubMed ID: 35619282
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress.
Chen HL; Chen HL; Yuan RH; Wu SH; Chen YH; Chien CS; Chou SP; Wang R; Ling V; Chang MH
J Cell Mol Med; 2012 Nov; 16(11):2679-89. PubMed ID: 22564513
[TBL] [Abstract][Full Text] [Related]
4. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
6. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine.
Zollner G; Fickert P; Fuchsbichler A; Silbert D; Wagner M; Arbeiter S; Gonzalez FJ; Marschall HU; Zatloukal K; Denk H; Trauner M
J Hepatol; 2003 Oct; 39(4):480-8. PubMed ID: 12971955
[TBL] [Abstract][Full Text] [Related]
7. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
Yu DD; Andrali SS; Li H; Lin M; Huang W; Forman BM
Bioorg Med Chem; 2016 Sep; 24(18):3986-3993. PubMed ID: 27372840
[TBL] [Abstract][Full Text] [Related]
8. [Disturbances in biliary secretion during tissue hypoxia and attempts at their corrections].
Hovorukha TM; Nazarenko AI; Zhalilo LI; Fil' HB; Baban VM; Seredenko MM
Fiziol Zh (1994); 2002; 48(1):35-40. PubMed ID: 11928630
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice.
Takigawa T; Miyazaki H; Kinoshita M; Kawarabayashi N; Nishiyama K; Hatsuse K; Ono S; Saitoh D; Seki S; Yamamoto J
Am J Physiol Gastrointest Liver Physiol; 2013 Sep; 305(6):G427-38. PubMed ID: 23868404
[TBL] [Abstract][Full Text] [Related]
10. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
11. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholic acid on hepatic LDL binding and uptake in dietary hypercholesterolemic hamsters.
Ceryak S; Bouscarel B; Malavolti M; Robins SJ; Caslow KL; Fromm H
Atherosclerosis; 2000 Nov; 153(1):59-67. PubMed ID: 11058700
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes.
Weitzel C; Stark D; Kullmann F; Schölmerich J; Holstege A; Falk W
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):169-77. PubMed ID: 15674094
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid increases low-density lipoprotein binding, uptake and degradation in isolated hamster hepatocytes.
Bouscarel B; Fromm H; Ceryak S; Cassidy MM
Biochem J; 1991 Dec; 280 ( Pt 3)(Pt 3):589-98. PubMed ID: 1764022
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid.
Henzel K; Thorborg C; Hofmann M; Zimmer G; Leuschner U
Biochim Biophys Acta; 2004 Feb; 1644(1):37-45. PubMed ID: 14741743
[TBL] [Abstract][Full Text] [Related]
17. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
18. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice.
Chen YS; Liu HM; Lee TY
Cells; 2019 Mar; 8(3):. PubMed ID: 30884843
[TBL] [Abstract][Full Text] [Related]
20. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
